A lyophilised formulation of chimpanzee adenovirus vector for long-term stability outside the deep-freeze cold chain.

ABSTRACT:

Background

The adenovirus-vaccine platform has come to prominence with the COVID-19 vaccination campaigns. The objective of this study was to validate a formulation that was suitable for lyophilisation and long-term storage at 5 (2-8) °C.

Methods

Vaccine stability was assessed up to five years at 5 °C using a lyophilised formulation of the chimpanzee-adenovirus vector ChAd155 encoding a respiratory syncytial virus (RSV) antigen. Vaccine potency was assessed by functional infectivity assay. Other assessments of vaccine stability included those for capsid integrity, particle content, and DNA release. Vaccine efficacy and safety were assessed after two years in a murine model of RSV challenge and a rabbit toxicology model, respectively.

Results

Here, we show that the pot

SUBMITTER: Mathot F 

PROVIDER: S-EPMC11742975 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature